204 related articles for article (PubMed ID: 34841595)
21. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
[TBL] [Abstract][Full Text] [Related]
22. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
[TBL] [Abstract][Full Text] [Related]
23. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
24. A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions.
Liu JC; Egan SE; Zacksenhaus E
Oncotarget; 2013 Aug; 4(8):1317-28. PubMed ID: 23945331
[TBL] [Abstract][Full Text] [Related]
25. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
26. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
27. High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.
Crozier JA; Barone J; Whitworth P; Cheong A; Maganini R; Tamayo JP; Dauer P; Wang S; Audeh W; Glas AM
J Surg Oncol; 2022 Mar; 125(4):596-602. PubMed ID: 34964996
[TBL] [Abstract][Full Text] [Related]
28. Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.
Beitsch P; Whitworth P; Baron P; Pellicane J; Treece T; Yoder E; Gittleman M;
Ann Surg Oncol; 2016 Oct; 23(10):3317-23. PubMed ID: 27384749
[TBL] [Abstract][Full Text] [Related]
29. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
30. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients.
Schroth W; Büttner FA; Kandabarau S; Hoppe R; Fritz P; Kumbrink J; Kirchner T; Brauer HA; Ren Y; Henderson D; Madden SF; Sauer G; Fehm T; Wallwiener D; Fasching PA; Mürdter T; Schwab M; Brauch H;
Clin Cancer Res; 2020 Dec; 26(24):6523-6534. PubMed ID: 33008814
[TBL] [Abstract][Full Text] [Related]
31. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
[TBL] [Abstract][Full Text] [Related]
32. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Whitworth P; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Nash CH; Murray MK; Richards PD; Gittleman M; Budway R; Rahman RL; Kelemen P; Dooley WC; Rock DT; Cowan K; Lesnikoski BA; Barone JL; Ashikari AY; Dupree B; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
Ann Surg Oncol; 2022 Apr; 29(7):4141-52. PubMed ID: 35378634
[TBL] [Abstract][Full Text] [Related]
33. Novel gene signatures for prognosis prediction in ovarian cancer.
Bao M; Zhang L; Hu Y
J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
[TBL] [Abstract][Full Text] [Related]
34. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
[No Abstract] [Full Text] [Related]
35. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
36. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
JAMA Oncol; 2017 Nov; 3(11):1503-1510. PubMed ID: 28662222
[TBL] [Abstract][Full Text] [Related]
37. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.
Kristensen VN; Vaske CJ; Ursini-Siegel J; Van Loo P; Nordgard SH; Sachidanandam R; Sørlie T; Wärnberg F; Haakensen VD; Helland Å; Naume B; Perou CM; Haussler D; Troyanskaya OG; Børresen-Dale AL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2802-7. PubMed ID: 21908711
[TBL] [Abstract][Full Text] [Related]
38. A specific gene expression signature for visceral organ metastasis in breast cancer.
Savci-Heijink CD; Halfwerk H; Koster J; Horlings HM; van de Vijver MJ
BMC Cancer; 2019 Apr; 19(1):333. PubMed ID: 30961553
[TBL] [Abstract][Full Text] [Related]
39. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
